

REMARKS/ARGUMENTS

Favorable action is requested.

Applicants provisionally elect as follows:

Group 1 - claims 112 to 118 inclusive.

Binding agent B which we understand to be anti-human IgG - claims 112 to 118 inclusive.

Label 5 - claims 112 to 118 inclusive.

Capsid Antigen (ii) - claims 112 to 118 inclusive. We understand capsid sequence 1 to 74 to be generic.

This election is made with traverse.

The first of the above Amendments (the insertion following page 6, line 21) to the Specification is from Exhibit 1 to the Declaration of Joseph E. Mueth at tab 1 from page 4, line 18 to page 6, line 24, inclusive. The only change is that SEQ ID NO. 1 has been changed to "Figure 9" since the two are otherwise identical.


The second Amendment (the insertion after page 43, line 15) to the Specification is from Exhibit 1 to the Declaration of Joseph E. Mueth at tab 1, page 62, line 9 to page 64, line 35, inclusive; from Exhibit 1 to the Declaration of Joseph E. Mueth, at tab 1, page 68, line 25 to page 69, line 3, inclusive; and from Exhibit 1 to the Declaration of Joseph E. Mueth, at tab 1, page 74, line 16 to page 76, line 12, inclusive.

In these passages, appropriate editorial changes have been made to sequence identification, Examples and Figures for consistency. No new matter has been introduced.

An action on the merits is requested.

Date: April 3, 2006

Respectfully submitted,



Joseph E. Mueth
Registration No. 20,532

225 South Lake Avenue, 8th Floor
Pasadena, California 91101
Telephone: (626) 584-0396
Facsimile: (626) 584-6862